Navigation Links
Exclusive agreement to distribute Affinity Biosensors' Archimedes system extends Malvern Instruments' biopharma solutions
Date:10/29/2012

SANTA BARBARA, Calif., and MALVERN, United Kingdom, Oct. 29, 2012 /PRNewswire-iReach/ -- Materials characterization company Malvern Instruments Ltd. (Malvern, UK) has signed an exclusive distribution agreement with Affinity Biosensors LLC (Santa Barbara, CA, USA) which will extend the range of solutions that Malvern offers to the biopharmaceutical sector. The distribution agreement covers all geographies outside the USA and Canada.

(Photo: http://photos.prnewswire.com/prnh/20121029/CG02066)

Under the terms of the agreement Malvern will distribute the Archimedes Particle Metrology system, developed and manufactured by Affinity Biosensors, through its subsidiaries in Europe and Asia. Malvern will establish a co-marketing arrangement with Affinity Biosensors in North America.

Archimedes, which won the Pittcon Editors Gold Award in 2010 and an R&D100 Award in 2010, employs a unique patented technology co-invented by the Massachusetts Institute of Technology (MIT) and Affinity Biosensors. Using the technique of Resonant Mass Measurement (RMM), Archimedes detects and counts particles and determines their mass and size with high resolution and accuracy, in small sample volumes. A key area of application is the measurement of protein aggregation in biotherapeutic formulations, which provides critical information needed to speed development and improve drug safety and efficacy. Archimedes provides the technology to both count and characterize aggregates, making it invaluable to biopharmaceutical manufacturers and developers.

"We are very pleased to be involved with this exciting new technology and to be adding it to our growing range of solutions for biopharmaceutical researchers," said Duncan Roberts, Business Development Director for Malvern. "Protein aggregation is a significant challenge in the development of protein-based drugs, and an area of increasing interest and potential regulation. Archimedes will sit alongside Malvern's Zetasizer and Viscotek systems, all of which deliver complementary solutions for customers in this fast growing pharmaceutical industry sector."

Affinity Biosensors' CEO Ken Babcock commented, "Archimedes has been adopted at many leading US biopharmaceutical companies. Our partnership with Malvern will extend Archimedes' reach worldwide, and we are glad to see it alongside Malvern's leading materials characterization technology. Archimedes users are sure to benefit from Malvern's world-class support and applications expertise."

Archimedes allows precise measurement of size and mass of particles with diameters down to 50nm. Measurements are unaffected by optical or shape variations, and gentle fluidics ensure that fragile aggregates are not disrupted. The instrument can measure high viscosity samples and consumes as little as 100µl of precious protein formulation.  Archimedes can accept particle concentrations up to 1x109 per ml, allowing direct study of undiluted high concentration formulations.

Archimedes can also differentiate between protein aggregates and silicone oil droplets in an injectable biopharmaceutical using buoyant mass measurement, something that no other technology can do at the submicron size scale.

Details of Malvern's rapidly expanding range of protein characterization solutions are available at www.malvern.com/protein-aggregation, with full descriptions and specifications for the new Archimedes systems at www.malvern.com/archimedes

Malvern and Malvern Instruments are registered trademarks of Malvern Instruments Ltd

About Malvern Instruments

Malvern Instruments is a market leader in measuring performance-controlling material properties. These include particle size, particle shape, zeta potential, molecular weight, size and conformation, rheological properties and chemical identification. Malvern delivers the systems, support and expertise that ensure the analytical integrity and productivity needed to drive research, development and manufacturing.

Malvern's measurement solutions for scientists, technologists and engineers advance continually through customer collaboration. Complementary materials characterization systems deliver inter-related measurements that reflect the complexities of particulates and disperse systems, nanomaterials and macromolecules. Combining intelligently implemented technologies with in-depth industry applications knowledge and support, Malvern provides customers with the competitive advantage they demand.

Headquartered in Malvern, UK, Malvern Instruments has subsidiary organizations in all major European markets, North America, China, Japan and Korea, a joint venture in India, a global distributor network and applications laboratories around the world. www.malvern.com

About Affinity Biosensors

Affinity Biosensors, located in Santa Barbara, California, manufactures refined analytical instruments based on resonant mass measurement. Its Archimedes Particle Metrology System has been adopted by numerous leading biopharmaceutical companies to measure protein aggregation in the submicron size range, and at industrial and academic institutions to characterize nanoparticles. Affinity Biosensors will continue to provide sales and support to its customers throughout North America. Affinity Biosensors is also developing RMM-based instruments for rapid antibiotic susceptibility testing and ultra-high precision measurements of cell growth. www.affinitybio.com

Please send sales enquiries to:
Alison Vines, Malvern Instruments Ltd
Enigma Business Park, Grovewood Road, Malvern, Worcestershire WR14 1XZ  UK
Tel: +44 (0) 1684 892456; Fax: +44 (0) 1684 892789 salesinfo@malvern.com

For North American sales enquiries, contact:
David Hopton, Affinity Biosensors
75D Robin Hill Rd, Santa Barbara, CA 93117
Tel: 1 760 565 6984 sales@affinitybio.com

For press information, please contact:
Trish Appleton, Kapler Communications
Tel: +44 (0)1480 471059  Fax: +44 (0)1480 471069  trish.appleton@kapleronline.com

Media Contact: David Hopton Affinity Biosensors, 7608085767, dhopton@affinitybio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Affinity Biosensors
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. "Babolat Play & Connect" - Worldwide Exclusive Event at the French Open
2. Modern Mobility Aids, Inc. Announces a Revised Agreement for the Acquisition of Lumigene
3. NJIT, Chinas Bengbu Glass Institute sign agreement for R&D, training
4. BGI, GMU, Mass. Eye and Ear and OUHSC announce agreement to sequence 100 human adenoviruses
5. Springer and the Beijing Normal University Press sign agreement on new book series
6. Premier Healthcare Renews Supplier Agreement with Masimo
7. Saladax Biomedical Enters into Master Collaboration Agreement with Bristol-Myers Squibb
8. BP Biofuels, Texas AgriLife Research sign agreement to advance biofuel feedstock development
9. Wiley signs collaboration agreement with the Asian Federation of Biotechnology
10. IU biologists offer clearer picture of how protein machine systems tweak gene expression
11. Unexpected crustacean diversity discovered in northern freshwater ecosystems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... January 19, 2017 According to a new report published ... 2014 - 2022," the global biometric sensor market is expected to garner $1.5 ... In 2015, Asia-Pacific dominated the global market and contributed ... Continue Reading ... ...
(Date:1/18/2017)... MINNETONKA, Minn. , Jan. 18, 2017 /PRNewswire/ ... eClinical technology company that supports the entire spectrum ... 2016 has been another record-breaking year for the ... and market interest in MedNet,s eClinical products and ... to the tremendous marketplace success of ...
(Date:1/12/2017)... 12, 2017  New research undertaken by Fit Small ... future.  1,000 participants were simply asked which office technology had ... may consider standard issue.  Insights on what will ... gathered from futurists and industry leaders including Penelope Trunk ... .  Some of these findings ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... LAVAL, QC , Jan. 24, 2017 /PRNewswire/ - ProMetic ... the "Corporation") announced today that its orally active lead ... Medicine ("PIM") designation by the UK Medicines and Healthcare ... Syndrome ("AS"). A PIM designation is ... promising candidate for the Early Access to Medicines Scheme ...
(Date:1/24/2017)... 23, 2017 According to a ... Type (Genetic, Cell-based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoiesis, ... & Biotech Companies, CRO) - Global Forecast to 2021", ... Mouse Model Market for the forecast period of 2016 ... 116.0 Million by 2021 from USD 73.3 Million in ...
(Date:1/23/2017)... NEW YORK , Jan. 23, 2017  Spherix ... development company committed to the fostering of technology and ... its active patent infringement lawsuits. Anthony ... we enter 2017, we will continue to communicate with ... Equitable IP and our due diligence on other patent ...
(Date:1/23/2017)... , Jan. 23, 2017  Alkahest Inc. ... treatments for neurodegenerative diseases and other age-related conditions, ... the company as Chief Medical Officer. In this ... clinical development activities at Alkahest and serve on ... most recently served as Executive Director at Dynavax, ...
Breaking Biology Technology: